Literature DB >> 28832971

Class I histone deacetylase inhibition improves pancreatitis outcome by limiting leukocyte recruitment and acinar-to-ductal metaplasia.

Marta Bombardo1, Enrica Saponara1, Ermanno Malagola1, Rong Chen1, Gitta M Seleznik1, Cecile Haumaitre2, Evans Quilichini2, Anja Zabel1, Theresia Reding1, Rolf Graf1,3, Sabrina Sonda1,3.   

Abstract

BACKGROUND AND
PURPOSE: Pancreatitis is a common inflammation of the pancreas with rising incidence in many countries. Despite improvements in diagnostic techniques, the disease is associated with high risk of severe morbidity and mortality and there is an urgent need for new therapeutic interventions. In this study, we evaluated whether histone deacetylases (HDACs), key epigenetic regulators of gene transcription, are involved in the development of the disease. EXPERIMENTAL APPROACH: We analysed HDAC regulation during cerulein-induced acute, chronic and autoimmune pancreatitis using different transgenic mouse models. The functional relevance of class I HDACs was tested with the selective inhibitor MS-275 in vivo upon pancreatitis induction and in vitro in activated macrophages and primary acinar cell explants. KEY
RESULTS: HDAC expression and activity were up-regulated in a time-dependent manner following induction of pancreatitis, with the highest abundance observed for class I HDACs. Class I HDAC inhibition did not prevent the initial acinar cell damage. However, it effectively reduced the infiltration of inflammatory cells, including macrophages and T cells, in both acute and chronic phases of the disease, and directly disrupted macrophage activation. In addition, MS-275 treatment reduced DNA damage in acinar cells and limited acinar de-differentiation into acinar-to-ductal metaplasia in a cell-autonomous manner by impeding the EGF receptor signalling axis. CONCLUSIONS AND IMPLICATIONS: These results demonstrate that class I HDACs are critically involved in the development of acute and chronic forms of pancreatitis and suggest that blockade of class I HDAC isoforms is a promising target to improve the outcome of the disease.
© 2017 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28832971      PMCID: PMC5647184          DOI: 10.1111/bph.13984

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  59 in total

1.  Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP.

Authors:  John C McGrath; Elliot Lilley
Journal:  Br J Pharmacol       Date:  2015-05-12       Impact factor: 8.739

Review 2.  Interplay between DNA repair and inflammation, and the link to cancer.

Authors:  Dawit Kidane; Wook Jin Chae; Jennifer Czochor; Kristin A Eckert; Peter M Glazer; Alfred L M Bothwell; Joann B Sweasy
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-01-13       Impact factor: 8.250

Review 3.  Regeneration and repair of the exocrine pancreas.

Authors:  L Charles Murtaugh; Matthew D Keefe
Journal:  Annu Rev Physiol       Date:  2014-10-24       Impact factor: 19.318

4.  Characterization of the regulation and function of zinc-dependent histone deacetylases during rodent liver regeneration.

Authors:  Jiansheng Huang; Emily Barr; David A Rudnick
Journal:  Hepatology       Date:  2013-05       Impact factor: 17.425

Review 5.  Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis.

Authors:  Angela L McCleary-Wheeler; Gwen A Lomberk; Frank U Weiss; Günter Schneider; Muller Fabbri; Tara L Poshusta; Nelson J Dusetti; Sandra Baumgart; Juan L Iovanna; Volker Ellenrieder; Raul Urrutia; Martin E Fernandez-Zapico
Journal:  Cancer Lett       Date:  2012-10-13       Impact factor: 8.679

6.  Highly sensitive peptide-4-methylcoumaryl-7-amide substrates for blood-clotting proteases and trypsin.

Authors:  S Kawabata; T Miura; T Morita; H Kato; K Fujikawa; S Iwanaga; K Takada; T Kimura; S Sakakibara
Journal:  Eur J Biochem       Date:  1988-02-15

7.  Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model.

Authors:  Zhi-Yuan Zhang; Hermann J Schluesener
Journal:  J Neuropathol Exp Neurol       Date:  2013-03       Impact factor: 3.685

8.  Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors.

Authors:  Geneviève P Delcuve; Dilshad H Khan; James R Davie
Journal:  Clin Epigenetics       Date:  2012-03-12       Impact factor: 6.551

9.  MS-275, a class I histone deacetylase inhibitor, protects the p53-deficient mouse against ischemic injury.

Authors:  Sean P Murphy; Rona J Lee; Megan E McClean; Heather E Pemberton; Takuma Uo; Richard S Morrison; Chinthasagar Bastian; Selva Baltan
Journal:  J Neurochem       Date:  2013-11-06       Impact factor: 5.372

Review 10.  The M1 and M2 paradigm of macrophage activation: time for reassessment.

Authors:  Fernando O Martinez; Siamon Gordon
Journal:  F1000Prime Rep       Date:  2014-03-03
View more
  6 in total

Review 1.  Molecular signaling in pancreatic ductal metaplasia: emerging biomarkers for detection and intervention of early pancreatic cancer.

Authors:  Xiaojia Li; Jie He; Keping Xie
Journal:  Cell Oncol (Dordr)       Date:  2022-03-15       Impact factor: 6.730

Review 2.  Selective Targeting of Epigenetic Readers and Histone Deacetylases in Autoimmune and Inflammatory Diseases: Recent Advances and Future Perspectives.

Authors:  Mohammed Ghiboub; Ahmed M I Elfiky; Menno P J de Winther; Nicola R Harker; David F Tough; Wouter J de Jonge
Journal:  J Pers Med       Date:  2021-04-23

3.  Enhanced proliferation of pancreatic acinar cells in MRL/MpJ mice is driven by severe acinar injury but independent of inflammation.

Authors:  Marta Bombardo; Ermanno Malagola; Rong Chen; Arcangelo Carta; Gitta M Seleznik; Andrew P Hills; Rolf Graf; Sabrina Sonda
Journal:  Sci Rep       Date:  2018-06-20       Impact factor: 4.379

Review 4.  Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells.

Authors:  Sijia Zhang; Lingjun Zhan; Xue Li; Zhenhong Yang; Yumin Luo; Haiping Zhao
Journal:  Int J Biol Sci       Date:  2021-08-03       Impact factor: 6.580

5.  Pharmacological inhibition and reversal of pancreatic acinar ductal metaplasia.

Authors:  Lais da Silva; Jinmai Jiang; Corey Perkins; Kalina Rosenova Atanasova; Julie K Bray; Gamze Bulut; Ana Azevedo-Pouly; Martha Campbell-Thompson; Xiaozhi Yang; Hesamedin Hakimjavadi; Srikar Chamala; Ranjala Ratnayake; Raad Z Gharaibeh; Chenglong Li; Hendrik Luesch; Thomas D Schmittgen
Journal:  Cell Death Discov       Date:  2022-09-02

6.  MicroRNA-495 suppresses pre-eclampsia via activation of p53/PUMA axis.

Authors:  Yi Zhao; Ge Zhao; Weiwei Li
Journal:  Cell Death Discov       Date:  2022-03-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.